These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1687505)

  • 1. Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.
    Poller DN; Galea M; Pearson D; Bell J; Gullick WJ; Elston CW; Blamey RW; Ellis IO
    Breast Cancer Res Treat; 1991 Dec; 20(1):3-10. PubMed ID: 1687505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?
    Barnes DM; Bartkova J; Camplejohn RS; Gullick WJ; Smith PJ; Millis RR
    Eur J Cancer; 1992; 28(2-3):644-8. PubMed ID: 1350456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.
    Poller DN; Snead DR; Roberts EC; Galea M; Bell JA; Gilmour A; Elston CW; Blamey RW; Ellis IO
    Br J Cancer; 1993 Jul; 68(1):156-61. PubMed ID: 8100443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
    Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
    Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia.
    Porter PL; Garcia R; Moe R; Corwin DJ; Gown AM
    Cancer; 1991 Jul; 68(2):331-4. PubMed ID: 1676930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of c-erbB3 protein in primary breast carcinomas.
    Naidu R; Yadav M; Nair S; Kutty MK
    Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.
    Somerville JE; Clarke LA; Biggart JD
    J Clin Pathol; 1992 Jan; 45(1):16-20. PubMed ID: 1346789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-erbB-2 protein and neuroendocrine expression in intraductal carcinomas of the breast.
    Lilleng R; Hagmar BM; Nesland JM
    Mod Pathol; 1992 Jan; 5(1):41-7. PubMed ID: 1347423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies].
    Edorh A; Parache RM; Migeon C; N'Sossani B; Rihn B
    Pathol Biol (Paris); 1995 Sep; 43(7):584-9. PubMed ID: 8570262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-erbB-2 oncoprotein in screen-detected breast carcinoma: an immunohistological study.
    Soomro S; Taylor P; Shepard HM; Feldmann M; Sinnett HD; Shousha S
    Int J Cancer; 1993 Aug; 55(1):63-5. PubMed ID: 8102130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry.
    Stål O; Sullivan S; Sun XF; Wingren S; Nordenskjöld B
    Cytometry; 1994 Jun; 16(2):160-8. PubMed ID: 7924685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
    Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
    Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus.
    Nakamura T; Nekarda H; Hoelscher AH; Bollschweiler E; Harbeck N; Becker K; Siewert JR; Harbec N [corrected to Harbeck N]
    Cancer; 1994 Apr; 73(7):1785-94. PubMed ID: 7907940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
    Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
    Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit.
    Kommoss F; Colley M; Hart CE; Franklin WA
    Mol Cell Probes; 1990 Feb; 4(1):11-23. PubMed ID: 1969111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.
    Gasparini G; Gullick WJ; Bevilacqua P; Sainsbury JR; Meli S; Boracchi P; Testolin A; La Malfa G; Pozza F
    J Clin Oncol; 1992 May; 10(5):686-95. PubMed ID: 1349034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neu (c-erbB-2), a tumor marker in carcinoma of the female breast.
    Maguire HC; Greene MI
    Pathobiology; 1990; 58(6):297-303. PubMed ID: 1981830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.